Literature DB >> 3943114

Laboratory models: some historical perspective.

H E Skipper.   

Abstract

Mesh：

Substances：

Year:  1986        PMID： 3943114

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  14 in total

1.  [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

Review 2.  Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.

Authors:  Amitkumar Mehta; Andres Forero-Torres
Journal:  Curr Oncol Rep       Date:  2015-09       Impact factor: 5.075

3.  The prisoner's dilemma as a cancer model.

Authors:  Jeffrey West; Zaki Hasnain; Jeremy Mason; Paul K Newton
Journal:  Converg Sci Phys Oncol       Date:  2016-07-04

4.  Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Authors:  Nicholas J Short; Christopher B Benton; Hsiang-Chun Chen; Peng Qiu; Lisa Gu; Sherry Pierce; Mark Brandt; Abhishek Maiti; Taejin L Min; Kiran Naqvi; Alfonso Quintas-Cardama; Marina Konopleva; Tapan Kadia; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Elias Jabbour; Hagop Kantarjian; Michael Andreeff
Journal:  Am J Hematol       Date:  2016-08-29       Impact factor: 10.047

5.  Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.

Authors:  Krastan B Blagoev; Julia Wilkerson; Wilfred D Stein; James Yang; Susan E Bates; Tito Fojo
Journal:  Cancer Res       Date:  2014-09-01       Impact factor: 12.701

Review 6.  Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer.

Authors:  Elizabeth Comen; Patrick G Morris; Larry Norton
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-09-26       Impact factor: 2.673

7.  Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.

Authors:  Pamela Drullinsky; Steven M Sugarman; Monica N Fornier; Gabriella D'Andrea; Teresa Gilewski; Diana Lake; Tiffany Traina; Carolyn Wasserheit-Lieblich; Nancy Sklarin; Deena Atieh-Graham; Nancy Mills; Tiffany Troso-Sandoval; Andrew D Seidman; Jeffrey Yuan; Hamangi Patel; Sujata Patil; Larry Norton; Clifford Hudis
Journal:  Clin Breast Cancer       Date:  2010-12-01       Impact factor: 3.225

8.  Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells.

Authors:  Donghai Jiang; Meihua Sui; Wangyan Zhong; Yuan Huang; Weimin Fan
Journal:  Cancer Lett       Date:  2013-03-07       Impact factor: 8.679

9.  Tumor growth instability and its implications for chemotherapy.

Authors:  Paolo Castorina; Daniela Carcò; Caterina Guiot; Thomas S Deisboeck
Journal:  Cancer Res       Date:  2009-10-27       Impact factor: 12.701

10.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.